Enrolling by invitationNCT06943365

Role of Anti-TREK-1 Autoantibodies in SCVF

Studying Idiopathic ventricular fibrillation

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Principal Investigator
Christian Steinberg, MD
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Intervention
Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies(other)
Enrollment
300 enrolled
Eligibility
18 years · All sexes
Timeline
2025 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06943365 on ClinicalTrials.gov

Other trials for Idiopathic ventricular fibrillation

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic ventricular fibrillation →

← Back to all trials